Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Timothy Brown | M | 57 | 31 years | |
Stacy Wolff | F | - | 27 years | |
Stephanie Dismore | F | 51 | 25 years | |
Kobi Elbaz | M | - | 28 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Todd F. Davenport | M | 73 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 years |
Jon Fong | M | - | 14 years | |
David Packard | M | - | 57 years | |
Michael Glen Dallas | M | 55 | - | |
William T. Hayes | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 years |
Daryl Raiford | M | 61 | 5 years | |
Gregory Lambrecht | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | - |
Didier Hirsch | M | 72 | 10 years | |
Charles N. Charnas | M | 65 | - | |
John A. Young | M | 91 | 34 years | |
Richard T. Spencer | M | 87 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 years |
Neil Dougherty | M | 55 | - | |
Martin Scott | M | 68 | 17 years | |
Ruth Lutes | F | - | 15 years | |
David B. Kirk | M | - | 2 years | |
San Mai | M | - | 10 years | |
Tarek Rizkalla | M | - | 3 years | |
Julie Ione Morris | F | - | 10 years | |
Rick Ellis | M | - | 17 years | |
Sharon Gross | F | - | 11 years | |
Joel W. Achramowicz | M | - | 10 years | |
Edmund J. Roschak | M | 57 | 4 years | |
Claudio Giuliano | M | 53 | 4 years | |
Aloke Gupta | M | - | 20 years | |
Bradley R. Anderson | M | 65 | - | |
Pranesh Anthapur | M | - | 2 years | |
Melanie Vinson | F | 54 | 8 years | |
John Liddicoat | M | 60 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 years |
Jonathan David Wagner | M | - | 1 years | |
Carol G. Mills | F | 70 | 5 years | |
Michael Sheridan | M | 62 | 13 years | |
Antonio Neri | M | 56 | 20 years | |
Frank Ostojic | M | - | - | |
Jonathan Rende | M | 59 | 1 years | |
David Mather | M | - | 8 years | |
Daryl Eicher | M | - | 3 years | |
Gregory Matz | M | 64 | 15 years | |
Jose Manuel Fernandez da Ponte | M | - | 2 years | |
Chris Summersgill | M | - | 2 years | |
George Sparks | M | - | 20 years | |
Jessica Denecour | F | 62 | 16 years | |
Anton Hanebrink | M | 47 | 10 years | |
Thi La | F | 59 | 11 years | |
Christopher Mierzwa | M | - | - | |
Louise Laforce | F | - | 2 years | |
David Gross | M | - | 11 years | |
Bee Choon Yeo | M | 65 | 17 years | |
Donn Raymond | M | - | 3 years | |
Jeffrey S. Henderson | M | 64 | - | |
Zvi Margalit | M | - | 3 years | |
Mario Fontana | M | 78 | 2 years | |
Frank M. Steranka | M | - | 1 years | |
Samuel L. Ginn | M | 87 | 6 years | |
John L. Doyle | M | 92 | 36 years | |
Richard C. Alberding | M | 93 | 33 years | |
Gary B. Eichhorn | M | 69 | 4 years | |
Richard Belluzzo | M | 71 | 23 years | |
Philip M. Condit | M | - | 6 years | |
Ruann Faye Ernst | M | 77 | 10 years | |
Carolyn M. Ticknor | F | 77 | 7 years | |
Condoleezza Rice | M | 69 | 2 years | |
Daniel C. Storey | M | 54 | 14 years | |
Wim Roelandts | M | 79 | 2 years | |
Ron Eller | M | 63 | 14 years | |
David Gai | M | 61 | 3 years | |
Shashank Samant | M | 54 | 2 years | |
Bruce Bromage | M | 70 | 7 years | |
Chiu Shun Lo | M | 67 | 12 years | |
Allison Johnson | F | 62 | 6 years | |
Richard D. Kniss | M | 82 | 4 years | |
D. Craig Nordlund | M | 74 | 12 years | |
Jean Nye | F | 71 | 19 years | |
Larry D. Mitchell | M | 82 | 29 years | |
Betsey Nelson | F | 63 | 9 years | |
Jef T. Graham | M | 68 | 15 years | |
Harri Eerik Koponen | M | 62 | 5 years | |
Peter Blackmore | M | 76 | 13 years | |
Kwong Sen Kiew | M | 76 | 14 years | |
Christopher D. Hutchins | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 8 years |
Sanjay Srivastava | M | - | 5 years | |
Kevin Negus | M | - | 10 years | |
Eric P. Buatois | M | 65 | 3 years | |
Mark R. Tauscher | M | 72 | 2 years | |
Eric Gonzales | M | - | 2 years | |
Neal J. Carney | M | 68 | 4 years | |
Robert Frankenberg | M | 76 | 25 years | |
Joel S. Birnbaum | M | 86 | 18 years | |
Richard S. Love | M | 86 | 35 years | |
William G. Parzybok | M | 82 | 7 years | |
Rodolfo Archbold | M | 70 | 12 years | |
Ron Nersesian | M | 64 | 12 years | |
Robert R. Walker | M | 72 | 5 years | |
Debra L. Dunn | F | 67 | - | |
J. Adriaan Theron | M | - | 12 years | |
Frank P. Carrubba | M | 86 | 9 years | |
Eric Johnson | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan M. Rourke
- Personal Network